64 results
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
net proceeds from this offering primarily to fund clinical development of its drug candidates, to fund research and development activities to expand
8-K
NRIX
Nurix Therapeutics Inc
12 Apr 24
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
5:12pm
of its drug candidates, to fund research and development activities to expand its pipeline and for working capital and general corporate purposes
424B5
NRIX
Nurix Therapeutics Inc
12 Apr 24
Prospectus supplement for primary offering
5:10pm
primarily to fund clinical development of our drug candidates, to fund research and development activities to expand our pipeline and for working capital … conducting our clinical trials, manufacturing and commercialization efforts, expanded research and development activities and costs associated
424B5
NRIX
Nurix Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:06pm
clinical development of our drug candidates, to fund research and development activities to expand our pipeline and for working capital and general … , manufacturing and commercialization efforts, expanded research and development activities and costs associated with operating as a public company
8-K
EX-99.1
qnwej9duddb1
10 Apr 24
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
7:02am
8-K
EX-99.1
5na9 hk9dfzph
15 Feb 24
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
4:01pm
8-K
EX-99.1
5eupdgdg1yqvy14lafws
12 Oct 23
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:03pm
8-K
EX-99.1
1tjru3v
13 Jul 23
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:18pm
8-K
EX-99.1
voxnhzkb gv
13 Apr 23
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:02pm
8-K
EX-99.1
trlmd1q
6 Oct 22
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
4:10pm
424B5
prett xdf
8 Jul 22
Prospectus supplement for primary offering
4:10pm